Sanofi, Translate Bio expand mRNA vaccine partnership in $2.3bn worth deal
The French vaccines company, which is part of Sanofi, signed a collaboration and license agreement deal worth up to $805m with Translate Bio in 2018 for developing mRNA
Skyline Therapeutics has announced that the US Food and Drug Administration (FDA) granted orphan drug designation (ODD) to its gene therapy, SKG1108, for the treatment of Retinitis Pigmentosa (RP), an inherited retinal disease.
Frontier Scientific identified and developed multiple synthetic processes to produce stannous protoporphyrin (SnPP) – the active pharmaceutical ingredient of RBT-9, an investigational drug entering a Phase 2 trial
The phase III IMpassion031 study assessing Tecentriq plus chemotherapy (Abraxane, albumin-bound paclitaxel, nab-paclitaxel, followed by doxorubicin and cyclophosphamide) comparison to placebo plus chemotherapy reached its primary endpoint by